Akoya Biosciences Acquires Quantitative Pathology Solutions Portfolio from PerkinElmer

MENLO PARK–(BUSINESS WIRE)—October 31, 2018—Akoya Biosciences (Akoya), a Telegraph Hill Partners (THP) company, has acquired PerkinElmer, Inc’s Quantitative Pathology Solutions (QPS) portfolio.  Akoya was founded in 2015 to commercialize the CODEX® multiparameter tissue analysis technology developed in the lab of Dr. Garry Nolan at Stanford University. PerkinElmer has grown its Phenoptics™ QPS platform to be an industry leader in multiplex immunofluorescence. This purchase establishes Akoya as a leading provider of quantitative tissue biomarker evaluation from discovery through translational and clinical research.

High-parameter analysis of biological tissue samples provides critical spatial context in studies of autoimmune disease, immune-oncology and many other research areas. The Phenoptics portfolio, with its Mantra®, Vectra® and Vectra Polaris® systems, provides the throughput and standardization required to support large-scale translational studies. Its multispectral imaging instruments, reagents, software and research services have been adopted by hundreds of labs globally. CODEX enables biomarker discovery with detection of up to 50 markers on a single tissue section with reagents and instrumentation that integrate with our customer’s existing microscopes. CODEX includes optimized assay reagents combined with validated antibodies labeled with proprietary CODEX Barcodes to enable a simple, automated workflow.

Concurrent with the acquisition, PerkinElmer’s QPS team’s management, R&D, sales and support staff have joined Akoya.    Akoya will continue to operate this team based out of the greater Boston area and maintain headquarters in Menlo Park, CA. Brian McKelligon will remain as Chief Executive Officer of Akoya and Terry Lo, General Manager of the QPS team at PerkinElmer, will join Akoya as President.

“With both the Phenoptics portfolio and CODEX, Akoya will provide our customers with a full suite of end-to-end solutions for high parameter tissue analysis,” said Brian McKelligon, CEO of Akoya. “We now have the team and technologies to develop and deliver transformational solutions in the rapidly advancing field of tissue imaging.”

“The PerkinElmer team has created a powerful solution already deployed at leading academic and biopharmaceutical companies with a focus on immuno-oncology,” said Terry Lo, President of Akoya. “We are excited to now join Akoya and catalyze further development of the QPS platform as a leading technology for tissue analysis.”

Telegraph Hill Partners has provided Akoya with additional funding to support further growth of the organization and continue technology and product development. “By having one company with the capabilities of QPS and CODEX, both PerkinElmer and THP saw the opportunity to establish the most advanced and complete solution for multiplexed tissue analysis,” said Robert Shepler, Managing Director of THP. “PerkinElmer was excellent throughout the process, and we look forward to further collaborations with them.”

Akoya will be demonstrating the latest developments from CODEX and the Phenoptics solutions at the SITC annual meeting in Washington, DC. on November 7-11.  To register for the event, visit us at:  akoyabio.com/sitc2018

 

About Akoya Biosciences

Akoya Biosciences develops innovative technologies for life science researchers to enable spatially-resolved, quantitative tissue phenotyping at the cellular and subcellular level. The combined technologies of Phenoptics and CODEX are fueling advances in next generation tissue analysis by providing comprehensive solutions including instrumentation, reagents and software.  Akoya Biosciences is headquartered in Menlo Park, CA

For more information, please visit https://www.akoyabio.com

Contact:  media@akoyabio.com

October 31st, 2018|News|